Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 13, 2004

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions

Gaucher Disease

Interventions

DRUG

GA-GCB

15-60 U/kg every other week via intravenous infusion

Trial Locations (3)

Maria Sklodowska Curie Children's Hospital, Bucharest

Shaare Zedek Medical Center, Jerusalem

Mother and Child Health Care Institute of Serbia, Belgrade